##################################################################################
# Document Properties Section

SET DOCUMENT Name = "Document name"
SET DOCUMENT Description = "Document description"
SET DOCUMENT Version = "1.0"
SET DOCUMENT Copyright = "Copyright (c) 2012, Nanditha. All Rights Reserved."
SET DOCUMENT Authors = "Nanditha"
SET DOCUMENT Licenses = "Document license"
SET DOCUMENT ContactInfo = "your@email.com"

##################################################################################
# NAMESPACE URLS

DEFINE NAMESPACE ADO AS URL "http://belief.scai.fraunhofer.de/openbel/repository/namespaces/ADO.belns"
DEFINE NAMESPACE AFFX AS URL "http://resource.belframework.org/belframework/20150611/namespace/affy-probeset-ids.belns"
DEFINE NAMESPACE BRCO AS URL "http://belief.scai.fraunhofer.de/openbel/repository/namespaces/BRCO.belns"
DEFINE NAMESPACE CHEBI AS URL "http://resource.belframework.org/belframework/20150611/namespace/chebi.belns"
DEFINE NAMESPACE CHEBIID AS URL "http://resource.belframework.org/belframework/20150611/namespace/chebi-ids.belns"
DEFINE NAMESPACE CHEMBL AS URL "http://belief-demo.scai.fraunhofer.de/openbel/repository/namespaces/chembl-names.belns"
DEFINE NAMESPACE CHEMBLID AS URL "http://belief-demo.scai.fraunhofer.de/openbel/repository/namespaces/chembl-ids.belns"
DEFINE NAMESPACE CTO AS URL "http://belief.scai.fraunhofer.de/openbel/repository/namespaces/CTO.belns"
DEFINE NAMESPACE DO AS URL "http://resource.belframework.org/belframework/20150611/namespace/disease-ontology.belns"
DEFINE NAMESPACE DOID AS URL "http://resource.belframework.org/belframework/20150611/namespace/disease-ontology-ids.belns"
DEFINE NAMESPACE EGID AS URL "http://resource.belframework.org/belframework/20150611/namespace/entrez-gene-ids.belns"
DEFINE NAMESPACE FlyBase AS URL "http://belief.scai.fraunhofer.de/openbel/repository/namespaces/Dmel.belns"
DEFINE NAMESPACE GOBP AS URL "http://resource.belframework.org/belframework/20150611/namespace/go-biological-process.belns"
DEFINE NAMESPACE GOBPID AS URL "http://resource.belframework.org/belframework/20150611/namespace/go-biological-process-ids.belns"
DEFINE NAMESPACE GOCC AS URL "http://resource.belframework.org/belframework/20150611/namespace/go-cellular-component.belns"
DEFINE NAMESPACE GOCCID AS URL "http://resource.belframework.org/belframework/20150611/namespace/go-cellular-component-ids.belns"
DEFINE NAMESPACE HGNC AS URL "http://resource.belframework.org/belframework/20150611/namespace/hgnc-human-genes.belns"
DEFINE NAMESPACE LMSD AS URL "http://belief-demo.scai.fraunhofer.de/openbel/repository/namespaces/LMSD.belns"
DEFINE NAMESPACE MESHC AS URL "http://resource.belframework.org/belframework/20150611/namespace/mesh-chemicals.belns"
DEFINE NAMESPACE MESHCID AS URL "http://resource.belframework.org/belframework/20150611/namespace/mesh-chemicals-ids.belns"
DEFINE NAMESPACE MESHCS AS URL "http://resource.belframework.org/belframework/20150611/namespace/mesh-cellular-structures.belns"
DEFINE NAMESPACE MESHCSID AS URL "http://resource.belframework.org/belframework/20150611/namespace/mesh-cellular-structures-ids.belns"
DEFINE NAMESPACE MESHD AS URL "http://resource.belframework.org/belframework/20150611/namespace/mesh-diseases.belns"
DEFINE NAMESPACE MESHDID AS URL "http://resource.belframework.org/belframework/20150611/namespace/mesh-diseases-ids.belns"
DEFINE NAMESPACE MESHPP AS URL "http://resource.belframework.org/belframework/20150611/namespace/mesh-processes.belns"
DEFINE NAMESPACE MESHPPID AS URL "http://resource.belframework.org/belframework/20150611/namespace/mesh-processes-ids.belns"
DEFINE NAMESPACE MGI AS URL "http://resource.belframework.org/belframework/20150611/namespace/mgi-mouse-genes.belns"
DEFINE NAMESPACE NIFT AS URL "http://belief.scai.fraunhofer.de/openbel/repository/namespaces/NIFT.belns"
DEFINE NAMESPACE NTN AS URL "http://belief.scai.fraunhofer.de/openbel/repository/namespaces/Nutrition.belns"
DEFINE NAMESPACE PDO AS URL "http://belief.scai.fraunhofer.de/openbel/repository/namespaces/PDO.belns"
DEFINE NAMESPACE PH AS URL "http://belief-demo.scai.fraunhofer.de/openbel/repository/namespaces/Placeholder.belns"
DEFINE NAMESPACE PMIBP AS URL "http://belief-demo.scai.fraunhofer.de/BeliefDashboard/dicten/namespaces/pmibp.belns"
DEFINE NAMESPACE PMICHEM AS URL "http://belief-demo.scai.fraunhofer.de/BeliefDashboard/dicten/namespaces/pmichem.belns"
DEFINE NAMESPACE PMICOMP AS URL "http://belief-demo.scai.fraunhofer.de/BeliefDashboard/dicten/namespaces/pmicomp.belns"
DEFINE NAMESPACE PMIDIS AS URL "http://belief-demo.scai.fraunhofer.de/BeliefDashboard/dicten/namespaces/pmidis.belns"
DEFINE NAMESPACE PMIPFAM AS URL "http://belief-demo.scai.fraunhofer.de/BeliefDashboard/dicten/namespaces/pmipfam.belns"
DEFINE NAMESPACE PTS AS URL "http://belief.scai.fraunhofer.de/openbel/repository/namespaces/PTS.belns"
DEFINE NAMESPACE RGD AS URL "http://resource.belframework.org/belframework/20150611/namespace/rgd-rat-genes.belns"
DEFINE NAMESPACE SCHEM AS URL "http://resource.belframework.org/belframework/20150611/namespace/selventa-legacy-chemicals.belns"
DEFINE NAMESPACE SCOMP AS URL "http://resource.belframework.org/belframework/20150611/namespace/selventa-named-complexes.belns"
DEFINE NAMESPACE SDIS AS URL "http://resource.belframework.org/belframework/20150611/namespace/selventa-legacy-diseases.belns"
DEFINE NAMESPACE SFAM AS URL "http://resource.belframework.org/belframework/20150611/namespace/selventa-protein-families.belns"
DEFINE NAMESPACE SP AS URL "http://resource.belframework.org/belframework/20150611/namespace/swissprot.belns"
DEFINE NAMESPACE SPID AS URL "http://resource.belframework.org/belframework/20150611/namespace/swissprot-ids.belns"
DEFINE NAMESPACE dbSNP AS URL "http://belief.scai.fraunhofer.de/openbel/repository/namespaces/SNP.belns"


# ANNOTATION URLS

DEFINE ANNOTATION Anatomy AS URL "http://resource.belframework.org/belframework/20131211/annotation/anatomy.belanno"
DEFINE ANNOTATION BodyRegion AS URL "http://resource.belframework.org/belframework/1.0/annotation/mesh-body-region.belanno"
DEFINE ANNOTATION CardiovascularSystem AS URL "http://resource.belframework.org/belframework/1.0/annotation/mesh-cardiovascular-system.belanno"
DEFINE ANNOTATION Cell AS URL "http://resource.belframework.org/belframework/20131211/annotation/cell.belanno"
DEFINE ANNOTATION CellLine AS URL "http://resource.belframework.org/belframework/20131211/annotation/cell-line.belanno"
DEFINE ANNOTATION CellStructure AS URL "http://resource.belframework.org/belframework/20131211/annotation/cell-structure.belanno"
DEFINE ANNOTATION DigestiveSystem AS URL "http://resource.belframework.org/belframework/1.0/annotation/mesh-digestive-system.belanno"
DEFINE ANNOTATION Disease AS URL "http://resource.belframework.org/belframework/20131211/annotation/disease.belanno"
DEFINE ANNOTATION FluidAndSecretion AS URL "http://resource.belframework.org/belframework/1.0/annotation/mesh-fluid-and-secretion.belanno"
DEFINE ANNOTATION HemicAndImmuneSystem AS URL "http://resource.belframework.org/belframework/1.0/annotation/mesh-hemic-and-immune-system.belanno"
DEFINE ANNOTATION IntegumentarySystem AS URL "http://resource.belframework.org/belframework/1.0/annotation/mesh-integumentary-system.belanno"
DEFINE ANNOTATION MeSHAnatomy AS URL "http://resource.belframework.org/belframework/20131211/annotation/mesh-anatomy.belanno"
DEFINE ANNOTATION MeSHDisease AS URL "http://resource.belframework.org/belframework/20131211/annotation/mesh-diseases.belanno"
DEFINE ANNOTATION NervousSystem AS URL "http://resource.belframework.org/belframework/1.0/annotation/mesh-nervous-system.belanno"
DEFINE ANNOTATION RespiratorySystem AS URL "http://resource.belframework.org/belframework/1.0/annotation/mesh-respiratory-system.belanno"
DEFINE ANNOTATION Species AS URL "http://resource.belframework.org/belframework/20131211/annotation/species-taxonomy-id.belanno"
DEFINE ANNOTATION Tissue AS URL "http://resource.belframework.org/belframework/1.0/annotation/mesh-tissue.belanno"
DEFINE ANNOTATION UrogenitalSystem AS URL "http://resource.belframework.org/belframework/1.0/annotation/mesh-urogenital-system.belanno"
##################################################################################
# Statements Section

SET STATEMENT_GROUP = "Group 1"

# Add statements below this comment

# Citation :source,"first line",PubMed id"

########################################### 1 ###################################

SET Citation = {"PubMed","J Immunol. 2012 Jul 1;189(1):381-92. doi: 10.4049/jimmunol.1200409. Epub 2012 Jun 1.","22661091"}
SET Evidence = "The recruitment of neutrophils to the brain can contribute to neurotoxicity, 
particularly during acute brain injuries, such as cerebral ischemia, trauma, and seizures."

a("neutrophils") -- path(MESHD:"Neurotoxicity Syndromes")
a("neutrophils") -- path(MESHD:"Brain Ischemia")
a("neutrophils") -- a("trauma")
a("neutrophils") -- path(MESHD:"Seizures")

##########################################2##########################################

SET Citation = {"PubMed","J Neuroinflammation. 2012 Jun 20;9:135. doi: 10.1186/1742-2094-9-135.","22716035"}
SET Evidence = "In a mouse model of Alzheimer's disease (AD) the orally administered natural product 4'-O-methylhonokiol (MH) has been shown to prevent 
amyloidogenesis and progression of AD by inhibiting neuroinflammation."

SET Species = "10090"

a(MESHC:"4-O-methylhonokiol") -| path(MESHD:"Amyloidosis")
a(MESHC:"4-O-methylhonokiol") -| path(ADO:"neuroinflammation")

SET Evidence = "We argue that the novel cannabimimetic MH may exert its beneficial effects 
via modulation of CB₂ receptors expressed in microglial cells and astrocytes"

SET Cell ={"microglial cell","astrocyte"}

a(MESHC:"4-O-methylhonokiol") -- p(MGI:"Cnr2")

#########################################3#########################################

SET Citation = {"PubMed","Proteomics. 2012 Aug;12(15-16):2571-83. doi: 10.1002/pmic.201200024.","22778045"}
SET Evidence ="Pathway and network analysis indicate that hypothermia influences various biological functions of
glia such as molecular transport, cell movement, immune response, cell death, and stress response"

SET Species = "10090"
SET Cell = "glial cell"

path(MESHD:"Hypothermia") -> bp(MESHPP:"Cell Movement")
path(MESHD:"Hypothermia") -> bp(GOBP:"immune response")
path(MESHD:"Hypothermia") -> bp(MESHPP:"Cell Death")
path(MESHD:"Hypothermia") -> bp(GOBP:"regulation of response to stress")
path(MESHD:"Hypothermia") -> bp(MESHPP:"Biological Transport")

SET Evidence ="In conclusion, moderate hypothermia seems to have a significant effect on the protein expression 
profiles of brain glia and possibly ensuing neuroinflammation"

path(MESHD:"Hypothermia") -- bp(GOBP:"gene expression")
bp(GOBP:"gene expression") -- path(ADO:"neuroinflammation")

###########################################4############################################

SET Citation = {"PubMed","J Virol. 2012 Oct;86(19):10377-83. doi: 10.1128/JVI.01340-12. Epub 2012 Jul 11.","22787236"}
SET Evidence = "Neurodegenerative diseases are typically associated with an activation of glia and an increased level of cytokines"

SET Species = "10090"

path(MESHD:"Neurodegenerative Diseases") -- bp(GOBP:"regulation of cytokine activity")
path(MESHD:"Neurodegenerative Diseases") -- bp(GOBP:"microglial cell activation")

SET Evidence ="Here, in time course studies of C57BL/10 mice intracerebrally inoculated with 22L scrapie, 
abnormal protease-resistant prion protein (PrPres), astrogliosis, and microgliosis were first detected at 40 days
after intracerebral scrapie inoculation"

path(MESHD:"Scrapie") -> path(ADO:"astrocyte_activation")
path(MESHD:"Scrapie") -> path(ADO:"Microglial_activation")


SET Evidence ="In cytokine studies, IL-12p40 was first elevated by 60 days;
CCL3, IL-1β, and CXCL1 were elevated by 80 days; and CCL2 and CCL5 were elevated by 115 days."

path(MESHD:"Scrapie") -> p(MGI:Il12b)
path(MESHD:"Scrapie") -> p(MGI:Ccl3)
path(MESHD:"Scrapie") -> p(MGI:Il1b)
path(MESHD:"Scrapie") -> p(MGI:Cxcl1)
path(MESHD:"Scrapie") -> p(MGI:Ccl5)
path(MESHD:"Scrapie") -> p(MGI:Ccl2)

SET Evidence = "Thus, neither IL-12p40 nor IL-12p35 molecules were required for prion disease-associated 
neurodegeneration or neuroinflammation."

p(MGI:Il12b) causesNoChange path(MESHD:"Prion Diseases")
p(MGI:Il12a) causesNoChange path(MESHD:"Prion Diseases")


##################################################5#########################

SET Citation = {"PubMed","J Neuroinflammation. 2012 Jul 12;9:171. doi: 10.1186/1742-2094-9-171.","22788993"}
SET Species = "10090"

SET Evidence ="Production of the chemokine CCL2 by cells of the neurovascular unit (NVU) 
drives critical aspects of neuroinflammation"

SET NervousSystem = "Blood-Brain Barrier"
p(MGI:Ccl2)-- path(ADO:"neuroinflammation")

SET Evidence ="Accordingly, we sought to determine if the compound bindarit, which inhibits CCL2 synthesis"

a("bindarit") -| p(MGI:Ccl2)

SET Evidence = "Bindarit repressed CCL2 expression by all three cultured cells and 
antagonized upregulated expression of CCL2 in both brain and spinal cord in vivo following LPS administration"

SET Cell = {"astrocyte","microglial cell","cerebral cortex endothelial cell"}
a("bindarit") -| p(MGI:Ccl2)

SET Anatomy ={"brain","spinal cord"}
a("bindarit") -| p(MGI:Ccl2)

SET Evidence = " Bindarit also significantly modified the course and severity of clinical EAE,
diminished the incidence and onset of disease, and evidenced signs of disease reversal."

a("bindarit") -- a("experimental autoimmune encephalomyelitis")



###########################################6######################################

SET Citation = {"PubMed","J Neuroinflammation. 2012 Jul 20;9:177. doi: 10.1186/1742-2094-9-177.","22818222"}
SET Species = "9606" 

SET Evidence ="CCAAT enhancer-binding protein (C/EBP)β regulates gene expression in multiple organ systems and cell types, including astrocytes in the central nervous system (CNS)"
p(HGNC:IL1B) -- p(HGNC:CEBPB)

SET Evidence =" Inflammatory stimuli, interleukin (IL)-1β, 
tumor necrosis factor-α, human immunodeficiency virus (HIV)-1 and 
lipopolysaccharide induce astrocyte C/EBPβ expression."

a(SCHEM:Lipopolysaccharide) -> r(HGNC:CEBPB)
p(HGNC:TNF) -> r(HGNC:CEBPB)
p(HGNC:IL1B) -> r(HGNC:CEBPB)
a(SCHEM:"HIV-1") -> r(HGNC:CEBPB)

SET Evidence ="C/EBPβ is detectable in brains of Alzheimer's disease (AD), Parkinson's disease (PD) and HIV-1-associated dementia (HAD) patients,
yet little is known about how C/EBPβ contributes to astrocyte gene regulation during neuroinflammation."

path(MESHD:Dementia) -- path(MESHD:"Alzheimer Disease")


SET Evidence ="Astrocytes were treated with mitogen-activated protein kinase-selective inhibitors, 
then with IL-1β for 12 or 24 h followed by COX-2 and BDKRB2, expression analyses"

p(HGNC:IL1B) -- a(CHEBI:mitogen)
p(HGNC:PTGS2) -- a(CHEBI:mitogen)

SET Evidence = "Inhibiting extracellular-regulated kinase (ERK)1/2 
activation blocked IL-1β-induced BDKRB2 mRNA expression while increasing COX-2 expression."

p(HGNC:PTGS2) -- p(HGNC:MAPK3)  
p(HGNC:BDKRB2) -- p(HGNC:MAPK3)
p(HGNC:IL1B) -- p(HGNC:MAPK3)
p(HGNC:PTGS2) -- p(HGNC:IL1B)

SET Evidence ="Additionally, this work suggests p38K and ERK1/2 pathways may regulate gene expression in a 
complementary manner to fine tune the IL-1β-mediated astrocyte inflammatory response."

p(HGNC:IL1B) -> bp(GOBP:"inflammatory response")


############################################7#########################
SET Citation = {"PubMed","Proc Natl Acad Sci U S A. 2012 Aug 28;109(35):E2334-42. doi: 10.1073/pnas.1209577109. Epub 2012 Jul 23.","22826245"}

SET Species ="10090"

SET Evidence = "Here we investigated the contribution of astrocytes to neurodegeneration in multiple sulfatase deficiency (MSD), a severe lysosomal
storage disorder caused by mutations in the sulfatase modifying factor 1 (SUMF1) gene."

p(HGNC:SUMF1) -- a("multiple sulfatase deficiency")

SET Evidence ="behavioral analysis of mice with astrocyte-specific deletion of Sumf1 compared with mice with Sumf1 deletion in both astrocytes
 and neurons allowed us to link a subset of neurological manifestations of MSD to astrocyte dysfunction."
 
a("multiple sulfatase deficiency") -- a("astrocyte dysfunction")

#############################################8########################

SET Citation = {"PubMed","Oxid Med Cell Longev. 2012;2012:624925. doi: 10.1155/2012/624925. Epub 2012 Jul 8.","22829959"}

SET Evidence ="There is extensive evidence in Parkinson's disease of a link between oxidative stress and some of
 the monogenically inherited Parkinson's disease-associated genes. "

bp(MESHPP:"Oxidative Stress") --  a("Parkinson's disease-associated genes")

SET Evidence = "This paper focuses on the importance of this link and potential impact on neuronal function.
Basic mechanisms of oxidative stress, the cellular antioxidant machinery, and the main sources of cellular oxidative stress 
are reviewed. Moreover, attention is given to the complex interaction between oxidative stress and other prominent pathogenic pathways in 
Parkinson's disease, such as mitochondrial dysfunction and neuroinflammation. "

bp(MESHPP:"Oxidative Stress") -- path(ADO:"neuroinflammation")
bp(MESHPP:"Oxidative Stress") -- path(MESHD:"Mitochondrial Diseases")

##########################################9########################

SET Citation = {"PubMed","Exp Neurol. 2012 Oct;237(2):296-303. doi: 10.1016/j.expneurol.2012.07.010. Epub 2012 Jul 24.","22836148"}

SET Evidence = "Multiple sclerosis (MS) causes a variety of motor and sensory deficits and it is also associated with mood disturbances"

path(MESHD:"Multiple Sclerosis") -> a("Motor deficit")
path(MESHD:"Multiple Sclerosis") -> a("Sensory deficit")

SET Evidence = " First, we observed high anxiety indexes in EAE mice, preceding the appearance of motor defects. Then, we demonstrated
 that tumor necrosis factor α (TNF-α) has a crucial role in anxiety associated with neuroinflammation. "

path(ADO:"anxiety") -> a("motor defect")
p(MGI:Tnf) -- path(ADO:"anxiety")
path(ADO:"anxiety") -- path(ADO:"neuroinflammation")

###################################10#############################

SET Citation ={"PubMed","J Nucl Med. 2012 Sep;53(9):1383-91. doi: 10.2967/jnumed.112.105734. Epub 2012 Jul 31.","22851635"}
SET Evidence = "Arachidonic acid (AA) is found in high concentrations in brain phospholipids and is released as a second messenger
during neurotransmission and much more so during neuroinflammation and excitotoxicity."

bp(GOBP:"chemical synaptic transmission") -> a(CHEBI:"arachidonic acid")
path(ADO:"neuroinflammation") -> a(CHEBI:"arachidonic acid")

SET Evidence = "Upregulated brain AA metabolism associated with neuroinflammation has been imaged in rodents
 using [1-(14)C]AA and with PET in Alzheimer disease patients using [1-(11)C]AA."

SET Disease ="Alzheimer's disease"
a("arachidonic acid metabolism") -- path(ADO:"neuroinflammation")


#######################################11############################

SET Citation={"PubMed","Gene Ther. 2013 May;20(5):487-96. doi: 10.1038/gt.2012.58. Epub 2012 Aug 2.","22855093"}

SET Evidence = "Interleukin-25 (IL-25) is the only anti-inflammatory cytokine of the IL-17 family,
 and it has been shown to be efficacious in inhibiting neuroinflammation."

SET Species= "10090"

p(MGI:Il25) -| path(ADO:"neuroinflammation")

SET Evidence =" In both, we found that IL-25 gene therapy was able to modulate CNS myeloid cells, either infiltrating macrophages or resident microglia,
towards an anti-inflammatory, tissue-protective phenotype"
        
p(MGI:Il25) -> a("alternative activation of microglia")

##########################################12###########################

SET Citation = {"PubMed","PLoS One. 2012;7(7):e42078. doi: 10.1371/journal.pone.0042078. Epub 2012 Jul 31.","22860058"}
SET Species= "10090"

SET Evidence = "Molecular hydrogen has been shown to have neuroprotective effects in mouse models of acute neurodegeneration.
 The effect was suggested to be mediated by its free-radical scavenger properties."
 
a(MESHC:"Hydrogen") -| path(ADO:"neuroinflammation")
 
SET Evidence ="However, it has been shown recently that molecular hydrogen alters gene expression and protein phosphorylation."
 
a(MESHC:"Hydrogen") -- bp(GOBP:"gene expression")
a(MESHC:"Hydrogen") -- bp(MESHPP:"Phosphorylation")

SET Evidence = "We found that molecular hydrogen reduces the LPS-induced sickness behaviour and promotes recovery.
These effects are associated with a shift towards anti-inflammatory gene expression profile at baseline 
(downregulation of TNF- α and upregulation of IL-10). "
 
a(MESHC:"Hydrogen") -| a("LPS-induced sickness behaviour")
a(MESHC:"Hydrogen") -| p(MGI:Tnf)
a(MESHC:"Hydrogen") -> p(MGI:Il10)

UNSET Species
##############################################13#################

SET Citation = {"PubMed","J Vis Exp. 2012 Jul 23;(65). pii: 4097. doi: 10.3791/4097.","22872097"}

SET Evidence = "Microglia in a normal CNS express macrophage marker CD11b and exhibit a resting
phenotype by expressing low levels of activation markers such as CD45."

r(HGNC:CDK11B)
p(HGNC:PTPRC) -- p(HGNC:CDK11B)

SET Evidence = "MicroRNAs (miRNAs) are a growing family of conserved molecules (~22 nucleotides long)
that are involved in many normal physiological processes such as cell growth and differentiation(4) and pathologies 
such as inflammation(5)."

path(MESHD:Inflammation) -- bp(GOBP:"cell growth")


#####################################14###########################

SET Citation = {"PubMed","Nat Rev Neurol. 2012 Sep;8(9):518-30. doi: 10.1038/nrneurol.2012.156. Epub 2012 Aug 14.","22890216"}
SET Evidence = "GEP studies have implicated the ubiquitin-proteasome system in PD pathogenesis, and have provided evidence of 
mitochondrial dysfunction in PD and AD."

path(MESHD:"Parkinson Disease") -- p(HGNC:UBA52)


SET Evidence = "Lastly, in AD, a possible role for dysregulation of intracellular signalling pathways, 
including calcium signalling, has been highlighted."

a(SCHEM:Calcium) -- path(MESHD:"Alzheimer Disease")

###########################################15#########################

SET Citation = {"PubMed","J Neurosci. 2012 Aug 22;32(34):11511-23. doi: 10.1523/JNEUROSCI.0182-12.2012.","22915098"}

SET Evidence = "Nuclear factor κB activation impairs ependymal ciliogenesis and links neuroinflammation to hydrocephalus formation."
path(MESHD:Hydrocephalus) -- p(HGNC:NFKB1)

SET Evidence = "In this animal model, hydrocephalus formation is specifically induced during a critical time period of early postnatal development,
 in which IKK/NF-κB-induced neuroinflammation interferes with ependymal ciliogenesis."

p(HGNC:NFKB1) -- path(MESHD:Hydrocephalus)  

SET Evidence = "Therefore, our study might open up new perspectives for the treatment of certain types of neonatal and childhood 
hydrocephalus associated with hemorrhages and infections."

path(MESHD:Infection) -- path(MESHD:Hydrocephalus)
path(MESHD:Hemorrhage) -- path(MESHD:Hydrocephalus)


UNSET STATEMENT_GROUP

##################################################################################
# Statements Section

SET STATEMENT_GROUP = "Group 2"

# Add statements below this comment
##### paper 1 ###

SET Citation = {"PubMed","Neurotherapeutics. 2013 Jan;10(1):143-53. doi: 10.1007/s13311-012-0165-2."," 23296837"}

SET Evidence = "Consumption of coffee is associated with reduced risk of Parkinson's disease (PD), an effect that has largely been
 attributed to caffeine. However, coffee contains numerous components that may also be neuroprotective. One of these compounds is
 eicosanoyl-5-hydroxytryptamide (EHT), which ameliorates the phenotype of α-synuclein transgenic mice associated with decreased 
 protein aggregation and phosphorylation, improved neuronal integrity and reduced neuroinflammation. The neuroinflammatory 
 response to MPTP was markedly attenuated, and indices of oxidative stress and JNK activation were significantly prevented with 
 EHT"

a(CHEBI:caffeine) -- path(MESHD:"Parkinson Disease")
SET Species = "9606"
a("eicosanoyl-5-hydroxytryptamide") decreases  bp(MESHPP:"Aggregation")
a("eicosanoyl-5-hydroxytryptamide") decreases  bp(MESHPP:"Phosphorylation")
a("eicosanoyl-5-hydroxytryptamide") decreases  bp(ADO:"neuroinflammation")
#improved neuronal integrity?
a("eicosanoyl-5-hydroxytryptamide") decreases bp(MESHPP:"Oxidative Stress")
a("eicosanoyl-5-hydroxytryptamide") decreases act(p(HGNC:MAPK9))

SET Evidence = "Mice fed a diet containing EHT for four weeks exhibited dose-dependent preservation of nigral dopaminergic
 neurons following MPTP challenge compared to animals given control feed. Reductions in striatal dopamine and tyrosine 
 hydroxylase content were also less pronounced with EHT treatment."

SET NervousSystem = "Neostriatum"
a("eicosanoyl-5-hydroxytryptamide") increases a(CHEBI:"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine")
a("eicosanoyl-5-hydroxytryptamide") increases a(CHEBI:dopamine)
a("eicosanoyl-5-hydroxytryptamide") increases a(MGI:Th)
UNSET NervousSystem
UNSET Species

SET Evidence = "In cultured primary microglia and astrocytes, EHT had a direct anti-inflammatory effect demonstrated by 
repression of lipopolysaccharide-induced NFκB activation, iNOS induction, and nitric oxide production."
SET NervousSystem = {"Microglia","Astrocytes"}
a("eicosanoyl-5-hydroxytryptamide") decreases act(p(HGNC:LITAF))
a("eicosanoyl-5-hydroxytryptamide") decreases a("iNOS")
a("eicosanoyl-5-hydroxytryptamide") decreases a(CHEBI:"nitric oxide")
#couldnt find iNOS enzyme. ASk

UNSET NervousSystem 

# bel statement
SET Evidence = "Additionally, in SH-SY5Y cells, MPP(+)-induced demethylation of phosphoprotein phosphatase 2A (PP2A), the master 
 regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by EHT. "
 a("eicosanoyl-5-hydroxytryptamide") decreases g(MGI:Mpz)
 
#check where MPP is
############### paper 2 $$


SET Citation = {"PubMed","Anesthesiology. 2013 Mar;118(3):502-15. doi: 10.1097/ALN.0b013e3182834d77.","23314110"}
SET Evidence = " anesthesia with 3% sevoflurane for 2 h daily for 3 days induced cognitive impairment and neuroinflammation
 (e.g., increased interleukin-6 levels, 151 ± 2.3% [mean ± SD] vs. 100 ± 9.0%, P = 0.035, n = 6) in young but not in adult mice"
#how to diff between young and old mice
SET Species = "9606"
a(CHEBI:sevoflurane) -- path(ADO:"neuroinflammation")
a(CHEBI:sevoflurane) -- bp(ADO:"Mild_cognitive_impairment")

a(CHEBI:sevoflurane) -> p(MGI:Il6)

SET Evidence = " Anesthesia with 3% sevoflurane for 2 h daily for 1 day and 9% desflurane for 2 h daily for 3 days induced 
neither cognitive impairment nor neuroinflammation"
a(CHEBI:desflurane) decreases path(ADO:"neuroinflammation")
a(CHEBI:desflurane) decreases path(ADO:"Mild_cognitive_impairment")
p(MGI:Il6) -- a(CHEBI:sevoflurane)
UNSET Species
####################paper 3 $$


SET Citation = {"PubMed","Anesthesiology. 2013 Mar;118(3):502-15. doi: 10.1097/ALN.0b013e3182834d77.","24890099"}
SET Evidence = "Using a model of chronic neuroinflammation following murine cytomegalovirus (MCMV)-induced encephalitis, we found
that CD8(+) T-cells persisting within the brain expressed PD-1. Conversely, activated microglia expressed PD-L1. "
complex(p(HGNC:CD274),p(HGNC:SPATA2))
 
SET Evidence = "PD-L1 on microglia has been shown to negatively regulate T-cell activation in models of multiple sclerosis and acute viral encephalitis."
SET MeSHAnatomy = "Microglia"
bp(GOBP:"T cell activation") -- p(HGNC:CD274) 
UNSET MeSHAnatomy 

SET Evidence = "PD-L1 on microglia has been shown to negatively regulate T-cell activation in models of multiple sclerosis and acute viral encephalitis"
SET MeSHAnatomy = "Microglia"
path(MESHD:"Multiple Sclerosis") -- p(HGNC:CD274)
UNSET MeSHAnatomy

SET Evidence = "In vitro, primary murine microglia, which express low basal levels of PD-L1, upregulated the co-inhibitory ligand on IFN-γ-treatment."
p(HGNC:IFNG) -- p(HGNC:CD274)

SET Evidence = "Blockade of the PD-1: PD-L1 pathway in microglial: CD8(+) T-cell co-cultures increased T-cell IFN-γ and interleukin (IL)-2 production."
p(HGNC:IFNG) -- p(HGNC:CD274)
p(HGNC:IL2) -- p(HGNC:IFNG)
#PD-L1 is HGNC:CD274

SET Evidence = "Using ex vivo cultures of brain leukocytes, including microglia and CD8(+) T-cells, obtained from mice with MCMV-induced chronic 
neuroinflammation, we found that neutralization of either PD-1 or PD-L1 increased IFN-γ production from virus-specific CD8(+) T-cells stimulated with
 MCMV IE1168-176 peptide."

p(HGNC:IFNG) -- p(HGNC:CD274)

############paper4 : 24898638 ## $$$

SET Citation = {"PubMed","J Alzheimers Dis. 2014;42(2):421-33. doi: 10.3233/JAD-132165","24898638 "}

SET Evidence = "Metabolomic analyses of both whole blood and plasma showed a clear separation between untreated AL mice and the
other two groups, with levels of several metabolites involved in energy metabolism, including pyruvate and creatine, being 
significantly reduced in untreated AL mice compared with control and treated AL mice."
SET Species = "10090"

a(CHEBI:"beta-amyloid") increases a(pyruvate)
a(CHEBI:"beta-amyloid") increases a(creatine)

SET Evidence  = "Gallate treatment suppressed Aβ-induced overproduction of the inflammatory cytokine tumor necrosis factor-α in the hippocampus and 
normalized plasma levels of the affected metabolites."
SET MeSHAnatomy = "Hippocampus"
a(CHEBI:gallate) -| p(MGI:Tnf)
a(CHEBI:gallate) decreases act(a(CHEBI:"beta-amyloid"))
#a(CHEBI:gallate) -- p(MGI:App)
UNSET MeSHAnatomy
UNSET Species


########## paper 5 : 24898660### $

SET Citation = {"PubMed","J Alzheimers Dis. 2014;42(2):459-83. doi: 10.3233/JAD-140036.","24898660"}

SET Evidence = "The p75 neurotrophin receptor (p75NTR) is involved in degenerative mechanisms related to Alzheimer's disease (AD).
 In addition, p75NTR levels are increased in AD and the receptor is expressed by neurons that are particularly vulnerable in the
 disease. Therefore, modulating p75NTR function may be a significant disease-modifying treatment approach"

SET Species = "10090"
path(DO:"Alzheimer's disease") -> p(MGI:Ngfr)

SET Evidence = "Prior studies indicated that the non-peptide, small molecule p75NTR ligands LM11A-31, and chemically unrelated
 LM11A-24, could block amyloid-β-induced deleterious signaling and neurodegeneration in vitro, and LM11A-31 was found to mitigate
 neuritic degeneration and behavioral deficits in a mouse model of AD"
 
a("LM11A-24") decreases act(a(CHEBI:"beta-amyloid"))
a("LM11A-31") decreases act(a(CHEBI:"beta-amyloid"))
a("LM11A-31") decreases path(DO:"neurodegenerative disease") 
path(MESHD:"Alzheimer Disease") -- g(MGI:Ngfr)
path(MESHD:"Alzheimer Disease") -- g(MGI:App)
 
SET Evidence = " Both ligands decreased activation of microglia, while LM11A-31 attenuated reactive astrocytes"
 
SET Cell = "microglial cell"
a("LM11A-24") decreases bp(ADO:"Microglial_activation")
a("LM11A-31") decreases bp(ADO:"Microglial_activation")
UNSET CellLine 
UNSET Species 

####### paper 6 : 24907647 #####$$$

 
 SET Citation = {"PubMed","Toxicol In Vitro. 2014 Oct;28(7):1183-9. doi: 10.1016/j.tiv.2014.05.006. Epub 2014 Jun 4.","24907647"}
 
 SET Evidence = "2-Deoxy-d-glucose attenuates sevoflurane-induced neuroinflammation through nuclear factor-kappa B pathway in vitro."
 p(MGI:Nfkb1) -- a(CHEBI:"2-deoxy-D-glucose")
 
SET Evidence = " Mouse microglia cells were treated with 4.1% sevoflurane for 6h to examine the expression of interleukin (IL)-6 and tumor necrosis 
factor (TNF-α) and activation of nuclear factor-kappa B (NF-κB). Pyrrolidine dithiocarbamate (PDTC) or 2-DG was used 1h before sevoflurane treatment."
 
 SET Species = "10090" 
 SET Cell = "microglial cell"
a(CHEBI:sevoflurane) increases r(MGI:Il6)
a(CHEBI:sevoflurane) increases r(MGI: Tnf)
a(CHEBI:sevoflurane) increases act(p(MGI:Nfkb1))
 
a(CHEBI:"2-deoxy-D-glucose") decreases p(MGI:Il6)
a(CHEBI:"2-deoxy-D-glucose") decreases p(MGI: Tnf)
a(CHEBI:"2-deoxy-D-glucose") decreases p(MGI: Nfkb1)
 
UNSET Species

####### paper 7 : 24920309 ######$

 SET Citation = {"PubMed","J Neuroinflammation. 2014 Jun 11;11:104. doi: 10.1186/1742-2094-11-104","24920309"}
 SET Evidence = "Early passage human brain cell cultures were a mixture of microglia, astrocytes, fibroblasts and pericytes.
 Later passage cultures contained proliferating fibroblasts and pericytes only. Under basal culture conditions all cell types 
showed cytoplasmic NFκB indicating that they were in a non-activated state. Expression of IP-10 and MCP-1 were significantly 
increased in response to pro-inflammatory stimuli. The two chemokines were expressed in mixed cultures as well as cultures of
 fibroblasts and pericytes only. The expression of IP-10 and MCP-1 were regulated at the mRNA and protein level, and both were 
secreted into cell culture media. "
SET Species = "9606"
SET MeSHDisease = "Epilepsy"
SET Cell = {"microglial cell","astrocyte","fibroblast","pericyte cell"}
p(HGNC:CXCL10) -- path(MESHD:Inflammation)
p(HGNC:CCL2) -- path(MESHD:Inflammation)
UNSET Cell
UNSET MeSHDisease 
UNSET Species
#tloc(nuclear,p(HGNC:NFKB1))
    
###### paper 8 : 24928797 #######
  
SET Citation = {"PubMed","Nat Med. 2010 Aug;16(8):897-902. doi: 10.1038/nm.2183. Epub 2010 Jul 25.","24928797"}

SET Evidence = "Multiple system atrophy (MSA) is a sporadic, adult onset, relentlessly progressive neurodegenerative disease characterized by 
autonomic abnormalities associated with parkinsonism, cerebellar dysfunction, pyramidal signs, or combinations thereof."
SET Species = "10090" 
path(MESHD:"Parkinsonian Disorders") -- path(MESHD:"Multiple System Atrophy")
path(MESHD:"Cerebellar Diseases") -- path(MESHD:"Multiple System Atrophy")
path(MESHD:"Multiple System Atrophy") -- path(MESHD:"Neurodegenerative Diseases")

SET Evidence = "MSA is neuropathologically defined by the presence of α-synuclein-containing inclusions, particularly in the cytoplasm of 
oligodendrocytes (glial cytoplasmic inclusions, GCIs), which are associated with neurodegeneration."
p(MGI:Snca) -- path(MESHD:"Multiple System Atrophy")

SET Evidence = "The MSA neurodegenerative process likely comprises cell-to-cell transmission of α-synuclein in a prion-like manner, α-synuclein
 aggregation, increased oxidative stress, abnormal expression of tubulin proteins, decreased expression of neurotrophic factors, excitotoxicity and
 microglial activation, and neuroinflammation."
path(MESHD:"Multiple System Atrophy") -> bp(MESHPP:"Oxidative Stress")
path(MESHD:"Multiple System Atrophy") -| r(MGI:Ntf3)

SET Evidence = "These include sertraline, paroxetine, and lithium, which hamper arrival of α-synuclein to oligodendroglia; rifampicin, lithium,
and non-steroidal anti-inflammatory drugs, which inhibit α-synuclein aggregation in oligodendrocytes; riluzole, rasagiline, fluoxetine and mesenchymal
stem cells, which exert neuroprotective actions; and minocycline and intravenous immunoglobulins, which reduce neuroinflammation and microglial 
activation"
SET MeSHAnatomy = "Oligodendroglia"
a(CHEBI:"lithium atom") -| r(MGI:Snca)
a(CHEBI:sertraline) -| r(MGI:Snca)
a(CHEBI:paroxetine) -| r(MGI:Snca)

UNSET MeSHAnatomy
UNSET Species 

####### paper 9 : 24990149##### in process 

SET Citation = {"PubMed","Hum Mol Genet. 2014 Dec 1;23(23):6286-301. doi: 10.1093/hmg/ddu348. Epub 2014 Jul 2.","24990149"}
SET Species = "10090"
SET Evidence = "The role of inflammatory miRNAs in Alzheimer's disease (AD) and their ability to modulate glia responses are now 
beginning to be explored." 
SET Species = "10090"
a("inflammatory miRNAs") -- path(DO:"Alzheimer's disease")

SET Evidence = "In this study, we propose to disclose the functional role of miR-155, one of the most well studied immune-related miRNAs in AD-associated neuroinflammatory events, employing the 3xTg AD animal model."
g(MGI:Mir155) -- bp(ADO:"neuroinflammation")

SET Evidence = "This event occurred simultaneously with an increase of microglia and astrocyte activation, and before the 
appearance of extracellular Aβ aggregates, suggesting that less complex Aβ species, such as Aβ oligomers may contribute to early 
neuroinflammation."
SET MeSHDisease = "Alzheimer Disease"
m(MGI:Mir155) -> bp(ADO:"Microglial_activation")
m(MGI:Mir155) -> bp(ADO:"astrocyte_activation")
UNSET MeSHDisease

SET Evidence = "Our results suggest early miR-155 and c-Jun upregulation in the 3xTg AD mice, as well as in Aβ-activated 
microglia and astrocytes, thus contributing to the production of inflammatory mediators such as IL-6 and IFN-β."
g(MGI:Jun) -> g(MGI:Il6)
g(MGI:Mir155) -> g(MGI:Ifnb1)
UNSET Species
#check

###### paper 10 : 25008863##### in process

#check for IL-22RA2

SET Citation ={"PubMed","Genes Immun. 2014 Oct;15(7):457-65. doi: 10.1038/gene.2014.36. Epub 2014 Jul 10.","25008863"}
SET Evidence = "Single-nucleotide polymorphisms close to IL22RA2, coding for the soluble interleukin (IL)-22-binding protein 
(IL-22BP), are strongly and reproducibly associated with multiple sclerosis (MS),"
SET Species = "10090"
g(MGI:Il22ra2) -- path(DO:"multiple sclerosis")

SET Evidence = "Because IL-22BP is known to antagonize IL-22 signaling, a primarily pro-inflammatory cytokine, we hypothesized
 that the Il22ra2-deficient mice would have more severe EAE.Paradoxically, the knockout mice displayed a less severe disease course,
 less demyelination and less infiltration of immune cells in the CNS."
g(MGI:Il22ra2) -> path(MESHD:"Encephalomyelitis, Autoimmune, Experimental")

SET Evidence = "lack of IL-22BP leads to a higher availability of IL-22, which in the case of CNS inflammation, surprisingly acts
 in a protective fashion. Thus, deletion of the ortholog of the MS risk gene Il22ra2 in mice has beneficial effects on EAE, which 
may be considered in new therapeutic strategies for treating neuroinflammation"
g(MGI:Il22ra2) negativeCorrelation g(MGI:Il22) 
UNSET Species

###### paper 11 : 25019688####

SET Citation ={"PubMed","Neurosci Lett. 2014 Sep 5;579:18-23. doi: 10.1016/j.neulet.2014.07.003. Epub 2014 Jul 11.","25019688"}
SET Evidence = "Stroke induces a profound neuroinflammatory reaction that leads to secondary cerebral tissue injury. 
Interleukin-10 (IL-10) is a key anti-inflammatory cytokine that is endogenously produced by immune cells and limits this 
inflammatory reaction.Previously, therapeutic administration of IL-10 has been shown to be neuroprotective in experimental stroke"
SET Species = "10090"
path(MESHD:Stroke) -- path(DO:"cerebral infarction")
g(MGI:Il10) -| path(MESHD:Inflammation)
 
SET Evidence = "IL-10 treatment effectively downregulated pro-inflammatory signaling cascades which were upregulated by the 
ischemic lesion in the acute phase after the stroke. Our results emphasize the key role of IL-10 as a neuroprotective cytokine "
path(MESHD:Stroke) -- path(ADO:"ischemic_lesion") 
g(MGI:Il10) -| bp(ADO:neuroinflammation)
UNSET Species

###### paper 12 : 25051986#####
SET Citation = {"PubMed","J Neuroinflammation. 2014 Jul 23;11:126. doi: 10.1186/1742-2094-11-126.","25051986"}

SET Evidence = "Aging is characterized by a low-grade systemic inflammation that contributes to the pathogenesis of
 neurodegenerative disorders such as Alzheimer's disease (AD)."
SET Species = "10090"
path(MESHD:Inflammation) -- path(MESHD:"Alzheimer Disease")
path(MESHD:"Alzheimer Disease") -- path(MESHD:"Neurodegenerative Diseases")
bp(MESHPP:Aging) -- path(MESHD:Inflammation)

SET Evidence = "role of chromatin regulators in inflammation and longevity including the REST corepressor (Rcor)-2 factor,"
p(MGI:Rcor2) -- path(MESHD:Inflammation)

SET Evidence = "Rcor2 reduction in astrocytes was accompanied by an increased basal expression of the interleukin (Il)-6 gene.A negative correlation
between Rcor2 and Il6 gene expression was also verified in LPS-treated C6 glioma cells"
SET Cell = "astrocyte"
p(MGI:Rcor2) negativeCorrelation g(MGI:Il6)
UNSET Cell

SET Evidence = "Data presented here show interplay between Rcor2 downregulation and increased inflammation and suggest that
 Rcor2 may be a key regulator of inflammaging."
p(MGI:Rcor2) negativeCorrelation path(MESHD:Inflammation)
UNSET Species

###### paper 13 :25064079### $$$$

SET Citation = {"PubMed","Neurotoxicology. 2014 Sep;44:250-62. doi: 10.1016/j.neuro.2014.07.006. Epub 2014 Jul 23.","25064079"}

SET Evidence = "Neuroprotective effect of the chemical chaperone, trehalose in a chronic MPTP-induced Parkinson's disease mouse model."
SET Species = "10090"
path(MESHD:"Parkinson Disease") -- a(CHEBI:trehalose)
path(MESHD:"Parkinson Disease") -- a(CHEBI:"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine")

#SET Evidence = "The clinical features of PD emerge due to selective degeneration of dopamine (DA) neurons in the substantia nigra pars compacta (SNc),
#which project to the caudate putamen (CPu) where they release DA"
#check how to encode dopamine neuron

SET Evidence = " 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced damage to DA neurons. "
a(CHEBI:"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine") -- a(BRCO:"Ventral_tegmental_area_dopamine_neuron")

SET Evidence = "In the current in vivo mouse model study, we tested trehalose for its ability to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP)-induced damage to DA neurons."
a(CHEBI:"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine") -- a(CHEBI:"dAMP residue")

SET Evidence = "MPTP-induced losses in tyrosine hydroxylase and DA transporter immunoreactivity in the ventral midbrain SNc and CPu were significantly 
reduced by trehalose. Decreases in CPu dopamine levels produced by MPTP were also blocked by trehalose. Microglial activation and astrocytic hypertrophy
induced by MPTP were greatly reduced by trehalose, indicating protection against neuroinflammation."
a(CHEBI:trehalose) -- a(CHEBI:"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine")
a(CHEBI"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine") -| p(MGI:Th)
a(CHEBI:trehalose) -> p(MGI:Th)

SET Evidence = " Two tight junctional proteins, ZO-1 and occludin, are downregulated following MPTP treatment and trehalose blocks this effect"
a(CHEBI:trehalose) -> g(MGI:Tjp1)
a(CHEBI:trehalose) -> g(MGI:Ocln)

#SET Evidence = "the glucose transporter-1 that is expressed in brain endothelial cells is also protected by trehalose from MPTP-induced down-regulation"
UNSET Species  

####### paper 14 : 25086214 ###$$$

SET Citation = {"PubMed","Stem Cell Res. 2014 Sep;13(2):227-39. doi: 10.1016/j.scr.2014.06.001. Epub 2014 Jun 21.","25086214"}
SET Evidence = "cell migration is a crucial element in regenerative processes in MS, dictating the route of delivery, when cell transplantation is considered."
SET Species = "10090"
path(MESHD:"Multiple Sclerosis") -- bp(GOBP:"cell migration")

SET Evidence = "We have previously shown that inflammation triggers migration of multi-potential neural precursor cells (NPCs) into the white matter 
of experimental autoimmune encephalomyelitis (EAE) rodents, a widely used model of MS."
SET MeSHDisease = "Encephalomyelitis, Autoimmune, Experimental"
bp(GOBP:"cell migration") -- path(MESHD:Inflammation)
UNSET MeSHDisease

SET Evidence = "Stromal cell-derived factor-1α, monocyte chemo-attractant protein-1 and hepatocyte growth factor were expressed in the EAE brain and
specifically in microglia and astrocytes."
SET MeSHAnatomy = {"Microglia","Astrocytes"}
path(MESHD:Encephalomyelitis) -- r(MGI:Cxcl12)
path(MESHD:Encephalomyelitis) -- r(MGI:Hgf)
UNSET MeSHAnatomy

SET Evidence = "Selective blockage of CXCR4, CCR2 or c-Met partially inhibited NPC migration in EAE brains"
SET MeSHDisease = "Encephalomyelitis, Autoimmune, Experimental"
SET CellLine = NPC
g(MGI:Cxcr4) -> bp(GOBP:"cell migration")
g(MGI:Ccr2) -> bp(GOBP:"cell migration")
g(MGI:Met) -> bp(GOBP:"cell migration")
UNSET CellLine
UNSET MeSHDisease
UNSET Species

###paper 15 : 25086357#####

SET Citation = {"PubMed","Biochem Biophys Res Commun. 2014 Aug 22;451(2):239-45. doi: 10.1016/j.bbrc.2014.07.107. Epub 2014 Jul 30.","25086357"}

SET Evidence = "Microglia-mediated neuroinflammation is implicated in the pathogenesis of several neurodegenerative disorders."
path(ADO:neuroinflammation) -- path(ADO:"neurodegenerative_disease")

SET Evidence = "Rotenone is an environmental toxin that has been shown to activate microglia and neuroinflammation"
a(CHEBI:rotenone) -> bp(ADO:"Microglial_activation")
a(CHEBI:rotenone) -> path(ADO:"neuroinflammation")

SET Evidence = "rotenone enhanced the levels of M1 phenotypic genes including TNF-α, iNOS and COX-2/PGE2 but reduced that of M2 markers such as Ym1/2
 and IL-10 in mouse primary and immortalized microglia."
SET Species = "10090"
a(CHEBI:rotenone) -> g(MGI:Tnf)
a(CHEBI:rotenone) -> g(MGI:Nos2)
a(CHEBI:rotenone) -> g(MGI:Ptgs2)
a(CHEBI:rotenone) -| p(MGI:Il10)
UNSET Species
#check

SET Evidence = "transcription and protein expression of cystathionine-β-synthase (CBS), as well as hydrogen sulfide (H2S) production were decreased in 
rotenone-treated primary microglia."
a(CHEBI:rotenone) -| a(CHEBI:"EC 4.2.1.22 (cystathionine beta-synthase) inhibitor")
a(CHEBI:rotenone) -| a(CHEBI:"hydrogen sulfide")

SET Evidence = "via triggering ROS formation, rotenone suppressed the CBS-H2S pathway and thus promoted microglia polarization toward M1 
pro-inflammatory phenotype."

a(CHEBI:rotenone) -> a(CHEBI:"reactive oxygen species")

#### paper 16: 25093162####

SET Citation = {"PubMed","Biomed Res Int. 2014;2014:290182. doi: 10.1155/2014/290182. Epub 2014 Jul 1.","25093162"}

SET Evidence = "Tumor necrosis factor-α (TNF-α) is a critical proinflammatory cytokine regulating neuroinflammation. Elevated levels of TNF-α have 
been associated with various neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease"
g(MGI:Tnf) -- path(ADO:Neuroinflammation)
g(MGI:Tnf) -- path(MESHD:"Alzheimer Disease")

SET Evidence = "we report that RIP3-mediated necroptosis, a form of regulated necrosis, is activated in the mouse hippocampus after 
intracerebroventricular injection of TNF-α."
SET MeSHAnatomy = Hippocampus
g(MGI:Tnf) -> act(p(MGI:Ripk3))


SET Evidence = "IP3 deficiency attenuates TNF-α-initiated loss of hippocampal neurons."
g(MGI:Itpka) -- g(MGI:Tnf)
SET Evidence = " TNF-α promotes CYLD-RIP1-RIP3-MLKL-mediated necroptosis of hippocampal neurons largely bypassing ROS accumulation and calcium influx."
g(MGI:Tnf) -- g(MGI:Cyld)
g(MGI:Tnf) -- g(MGI:Ralbp1)
g(MGI:Tnf) -- g(MGI:Mprip)
g(MGI:Tnf) -- g(MGI:Mlkl)
g(MGI:Cyld) -- bp(GOBP:"execution phase of necroptosis")
g(MGI:Ralbp1) -- bp(GOBP:"execution phase of necroptosis")
g(MGI:Mprip) -- bp(GOBP:"execution phase of necroptosis")
g(MGI:Mlkl) -- bp(GOBP:"execution phase of necroptosis")
UNSET MeSHAnatomy

###### paper 17 : 25172655 ##### $$$$
SET Citation = {"PubMed","Biochem Biophys Res Commun. 2014 Sep 26;452(3):450-6. doi: 10.1016/j.bbrc.2014.08.092. Epub 2014 Aug 27.","25172655"}

SET Evidence = "Alcohol-induced neuroinflammation is mediated by the innate immunesystem."
SET Species = "10090"
a(CHEBI:alcohol) -- path(ADO:"neuroinflammation")

SET Evidence = "The miRNA miR-339-5p has previously been found to be upregulated in alcohol-induced neuroinflammation."
path(ADO:Neuroinflammation) -> g(MGI:Mlxip)

SET Evidence = "miR-339-5p inhibits alcohol-induced brain inflammation through regulating NF-κB pathway."
SET MeSHAnatomy = "Brain"
g(MGI:Mlxip) -| r(MGI:Nfkb1)
UNSET MeSHAnatomy

SET Evidence = "Our results show that alcohol induces transcription of miR 339-5p, IL-6, IL-1β and TNF-α in mouse brain 
tissue and isolated microglial cells by activating NF-κB. "

SET MeSHAnatomy = {"Brain","Tissues"} 
g(MGI:Nfasc) -> r(MGI:Mir339)
g(MGI:Nfasc) -> r(MGI:Il6)
g(MGI:Nfasc) -> r(MGI:Ptx3)
g(MGI:Nfasc) -> r(MGI:Tnf)
UNSET MeSHAnatomy 
UNSET Species